Do current cardiovascular risk prediction models have adequate calibration in the Southern Cone of Latin America?

2016-2017

  • Projects, Chronic Cardiovascular Health Projects, Projects of the Center of Excellence in Cardiovascular Health for the Southern Cone (CESCAS), Chronic Diseases Projects
  • Concluded

Period: 2016-2017

Researchers Dr. Pablo Gulayin, Prof. Dr. Adolfo Rubinstein, Dr. Vilma Irazola

Brief

The present study seeks to evaluate the calibration and behavior of cardiovascular risk prediction models in a population-based cohort from the Southern Cone of Latin America. The results of this research will provide valuable information for improving the classification and detection of patients with high cardiovascular risk.

Objective

1) To evaluate the calibration and discrimination of different cardiovascular risk equations (Framingham Heart Study, PROCAM, QRISK, SCORE and INTERHEART) in the population of a population-based cohort in the Southern Cone of Latin America; 2) evaluate the relationship between C-reactive protein (CRP) levels and the incidence of cardiovascular events in a subsample of participants at high cardiovascular risk; and 3) evaluate the impact on the re-classification of patients from the incorporation of PCR to the studied models.

Summary

Cardiovascular disease is the leading cause of death in the developed and developing world. In the clinical management of primary cardiovascular prevention, the calculation of global cardiovascular risk plays a central role in decision-making for the management of risk factors. However, most of the equations for calculating said risk have been developed in countries with socio-demographic, epidemiological and nutritional realities different from those of the countries of the Southern Cone of Latin America. The objective of this study is to evaluate the behavior of the most used current risk prediction models in a population-based cohort from the Southern Cone. The results of this study will provide extremely valuable information for improving the classification and detection of patients with high cardiovascular risk.

Finance

NIH–UJMT Fogarty Global Health